JNJ-61186372
Showing 1 - 25 of 437
Lung Cancer, Non Small Cell Lung Cancer Trial in Aurora (Amivantamab 1050mg, Amivantamab 1400mg, Amivantamab (to be determined))
Not yet recruiting
- Lung Cancer
- Non Small Cell Lung Cancer
- Amivantamab 1050mg
- +2 more
-
Aurora, Colorado
- +2 more
Apr 25, 2023
Lung Non-Small Cell Carcinoma Trial (Amivantamab, Biospecimen Collection, Computed Tomography)
Not yet recruiting
- Lung Non-Small Cell Carcinoma
- Amivantamab
- +3 more
- (no location specified)
Oct 30, 2023
NSCLC Trial (Amivantamab, Lazertinib, Doxycycline)
Not yet recruiting
- Carcinoma, Non-Small-Cell Lung
- Amivantamab
- +6 more
- (no location specified)
Nov 7, 2023
NSCLC Trial in Korea, Republic of, Malaysia, United States (Cetrelimab, Amivantamab)
Recruiting
- Carcinoma, Non-Small-Cell Lung
-
Fairfax, Virginia
- +3 more
Jun 16, 2023
Metastatic NSCLC Trial (Amivantamab)
Approved for marketing
- Metastatic Non-Small Cell Lung Cancer
- (no location specified)
Jun 28, 2021
NSCLC Trial in Worldwide (Dexamethasone, Montelukast, Methotrexate)
Not yet recruiting
- Carcinoma, Non-Small-Cell Lung
- Dexamethasone
- +4 more
-
Fountain Valley, California
- +17 more
Jan 31, 2023
Metastatic Non Small Cell Lung Cancer, Recurrent Non Small Cell Lung Cancer Trial in United States (Amivantamab, Lazertinib)
Recruiting
- Metastatic Non Small Cell Lung Cancer
- Recurrent Non Small Cell Lung Cancer
-
Basking Ridge, New Jersey
- +6 more
Aug 1, 2022
NSCLC Trial in Worldwide (Lazertinib, Amivantamab, Carboplatin)
Recruiting
- Carcinoma, Non-Small-Cell Lung
- Lazertinib
- +3 more
-
Los Angeles, California
- +83 more
Jan 31, 2023
Carcinoma, Non-small-Cell Lung Trial in Worldwide (Amivantamab, Lazertinib, Carboplatin)
Not yet recruiting
- Carcinoma, Non-small-Cell Lung
- Amivantamab
- +3 more
-
Westwood, Kansas
- +47 more
Aug 17, 2022
NSCLC Trial in Worldwide (Capmatinib, Amivantamab)
Not yet recruiting
- Carcinoma, Non-Small-Cell Lung
-
Orange, California
- +40 more
Aug 3, 2022
Metastatic Non Small Cell Lung Cancer Trial in Worldwide (Lazertinib, Amivantamab Subcutaneous and Co-Formulated with
Recruiting
- Advanced or Metastatic Non-small Cell Lung Cancer
- Lazertinib
- +2 more
-
Duarte, California
- +208 more
Jan 31, 2023
Advanced Solid Malignancies Trial in Worldwide (Ami-LC-MD, Ami-LC, Ami-HC)
Recruiting
- Advanced Solid Malignancies
- Ami-LC-MD
- +4 more
-
West Hollywood, California
- +13 more
Jan 31, 2023
Advanced or Metastatic Colorectal Cancer Trial in Worldwide (Amivantamab, Fluorouracil, Leucovorin)
Recruiting
- Advanced or Metastatic Colorectal Cancer
- Amivantamab
- +4 more
-
Birmingham, Alabama
- +85 more
Jan 27, 2023
NSCLC Trial in Worldwide (Amivantamab, Pemetrexed, Carboplatin)
Active, not recruiting
- Carcinoma, Non-Small-Cell Lung
- Amivantamab
- +2 more
-
Duarte, California
- +228 more
Jan 31, 2023
NSCLC Trial in Worldwide (Lazertinib, Amivantamab, Pemetrexed)
Recruiting
- Carcinoma, Non-Small-Cell Lung
- Lazertinib
- +3 more
-
Phoenix, Arizona
- +303 more
Aug 17, 2022
NSCLC Trial in Worldwide (Amivantamab, Osimertinib, Lazertinib)
Active, not recruiting
- Carcinoma, Non-Small-Cell Lung
- Amivantamab
- +3 more
-
Goodyear, Arizona
- +266 more
Aug 17, 2022
Advanced Prostate Cancer Trial in Lyon, Villejuif, Rotterdam (JNJ-78278343, JNJ-87189401)
Not yet recruiting
- Advanced Prostate Cancer
-
Lyon, France
- +2 more
Oct 18, 2023
Myeloproliferative Disorders, Essential Thrombocythemia, Tumors Trial (JNJ-88549968)
Not yet recruiting
- Myeloproliferative Disorders
- +3 more
- (no location specified)
Nov 21, 2023
Prostatic Tumors, Metastatic Castration-Resistant Prostate Cancer Trial in Worldwide (Abiraterone Acetate, Prednisone,
Active, not recruiting
- Prostatic Neoplasms
- Metastatic Castration-Resistant Prostate Cancer
- Abiraterone Acetate
- +2 more
-
Los Angeles, California
- +6 more
Jan 18, 2023
Metastatic Castration-resistant Prostate Tumors Trial in Australia, Korea, Republic of, United States (JNJ-78278343, Cetrelimab)
Not yet recruiting
- Metastatic Castration-resistant Prostate Neoplasms
-
Sarasota, Florida
- +7 more
Apr 6, 2023